JP2022547434A5 - - Google Patents

Info

Publication number
JP2022547434A5
JP2022547434A5 JP2022513525A JP2022513525A JP2022547434A5 JP 2022547434 A5 JP2022547434 A5 JP 2022547434A5 JP 2022513525 A JP2022513525 A JP 2022513525A JP 2022513525 A JP2022513525 A JP 2022513525A JP 2022547434 A5 JP2022547434 A5 JP 2022547434A5
Authority
JP
Japan
Prior art keywords
cancer
group
dendrimer
targeting agent
kda
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022513525A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022547434A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2020/050910 external-priority patent/WO2021035310A1/en
Publication of JP2022547434A publication Critical patent/JP2022547434A/ja
Publication of JP2022547434A5 publication Critical patent/JP2022547434A5/ja
Priority to JP2025153569A priority Critical patent/JP2026026483A/ja
Pending legal-status Critical Current

Links

JP2022513525A 2019-08-28 2020-08-28 標的化デンドリマー複合体 Pending JP2022547434A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025153569A JP2026026483A (ja) 2019-08-28 2025-09-16 標的化デンドリマー複合体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2019903152A AU2019903152A0 (en) 2019-08-28 Targeted Dendrimer Conjugates
AU2019903152 2019-08-28
PCT/AU2020/050910 WO2021035310A1 (en) 2019-08-28 2020-08-28 Targeted dendrimer conjugates

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025153569A Division JP2026026483A (ja) 2019-08-28 2025-09-16 標的化デンドリマー複合体

Publications (2)

Publication Number Publication Date
JP2022547434A JP2022547434A (ja) 2022-11-14
JP2022547434A5 true JP2022547434A5 (enExample) 2023-09-04

Family

ID=74683233

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022513525A Pending JP2022547434A (ja) 2019-08-28 2020-08-28 標的化デンドリマー複合体
JP2025153569A Pending JP2026026483A (ja) 2019-08-28 2025-09-16 標的化デンドリマー複合体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025153569A Pending JP2026026483A (ja) 2019-08-28 2025-09-16 標的化デンドリマー複合体

Country Status (9)

Country Link
US (1) US20220288216A1 (enExample)
EP (1) EP4021511A4 (enExample)
JP (2) JP2022547434A (enExample)
KR (1) KR20220052960A (enExample)
CN (1) CN114502201B (enExample)
AU (1) AU2020338481B2 (enExample)
BR (1) BR112022003628A2 (enExample)
CA (1) CA3149263A1 (enExample)
WO (1) WO2021035310A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180326081A1 (en) * 2011-06-06 2018-11-15 Starpharma Pty Ltd Macromolecules
JP7541978B2 (ja) * 2018-11-29 2024-08-29 スターファーマ ピーティーワイ エルティーディー 治療および画像化のためのデンドリマー
WO2023283537A2 (en) * 2021-07-07 2023-01-12 Institute For Systems Biology Cell analysis methods, compositions, and uses
EP4430076A2 (en) 2021-11-08 2024-09-18 Life Technologies AS Polymer-interaction molecule conjugates and methods of use
CN115991880B (zh) * 2022-12-08 2024-03-19 中国药科大学 一种树状大分子pamam-g5-tco及其制备方法与应用
WO2024182810A2 (en) * 2023-03-02 2024-09-06 Inmune Bio Inc. Bioconjugates of dominant negative tnf
KR20250100878A (ko) * 2023-12-26 2025-07-04 주식회사 압타머사이언스 분지형의 효소 절단 가능한 링커-페이로드와 이의 효율적인 제조방법
WO2025164814A1 (en) * 2024-02-01 2025-08-07 The University Of Tokyo Selective intracellular delivery of protein in cells with nanocarriers sensing cathepsin b activity
WO2025222234A1 (en) * 2024-04-24 2025-10-30 Starpharma Pty Ltd Targeted dendrimer conjugates
WO2026046228A1 (zh) * 2024-08-27 2026-03-05 苏州拓界医药有限公司 树枝状聚合物偶联物及其制备方法
CN119638781B (zh) * 2025-02-20 2025-05-16 瑞博(苏州)制药有限公司 一种抗体偶联药物连接子的合成方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008017122A1 (en) * 2006-08-11 2008-02-14 Starpharma Pty Ltd Polylysine dendrimer contrast agent
JP2010523595A (ja) * 2007-04-04 2010-07-15 マサチューセッツ インスティテュート オブ テクノロジー ポリ（アミノ酸）ターゲッティング部分
CN102596922A (zh) * 2009-10-06 2012-07-18 免疫基因公司 有效的缀合物和亲水性连接体
IN2014DN00101A (enExample) * 2011-06-06 2015-05-15 Starpharma Pty Ltd
US20160106856A1 (en) * 2012-08-14 2016-04-21 Angiochem Inc. Conjugates including an antibody moiety, a polypeptide that traverses the blood-brain barrier, and a cytotoxin

Similar Documents

Publication Publication Date Title
JP2022547434A5 (enExample)
TWI804499B (zh) Ror1抗體免疫接合物
US20240173427A1 (en) Glypican 3 antibodies and conjugates thereof
ES2543201T3 (es) Métodos y agentes que mejoran la dirección a las células tumorales que expresan CD138
JP2023511774A5 (enExample)
AU2020338481B2 (en) Targeted dendrimer conjugates
JP2022525704A5 (enExample)
JP2023535443A5 (enExample)
EP4087613A1 (en) Anti-slc34a2 antibodies, antibody drug conjugates, and methods of use thereof
JP2020525542A5 (enExample)
JP2024501121A5 (enExample)
JP2021505540A (ja) 乳がんの処置のためのヒト化抗ｌｉｖ１抗体
JP2025517476A5 (enExample)
JP2024525624A (ja) 抗体薬物コンジュゲート及びその使用
JP2024501894A5 (enExample)
JP2008515889A5 (enExample)
TW201905000A (zh) 含有抗globo h抗體之抗體－藥物共軛物及其用途
US11110179B2 (en) Combination of CD33 antibody drug conjugates with chemotherapeutic agents
JP2024539989A5 (enExample)
CN1345336A (zh) 抗体和趋化因子构建物及其在自身免疫疾病治疗中的用途
TW202131950A (zh) 依序抗ｃｄ１９療法
US20250295800A1 (en) Conjugate of a single domain antibody, a saponin and an effector molecule, pharmaceutical composition comprising the same, therapeutic use of said pharmaceutical composition
JP2026512687A (ja) ヒト化ｌ１ｃａｍ抗体－薬物複合体
JP2025519980A (ja) Ｐｄ－１阻害剤またはｐｄ－ｌ１阻害剤およびクローディン１８．２を標的にする抗体－薬物コンジュゲートによるがん処置
US20250127916A1 (en) Antibody drug conjugate (adc) targeting nectin 4 and comprising an exatecan payload